Literature DB >> 3531518

Design and synthesis of a potent and specific renin inhibitor with a prolonged duration of action in vivo.

S Thaisrivongs, D T Pals, D W Harris, W M Kati, S R Turner.   

Abstract

A structure-activity analysis of peptides containing backbone C alpha-methyl and N alpha-methyl modifications led to the discovery of potent renin inhibitors with high metabolic stability. In vitro, Boc-Pro-Phe-N alpha-MeHis-Leu psi-[CHOHCH2]Val-Ile-Amp (XII) is a potent inhibitor of human plasma renin with IC50 of 0.26 nM. It is a much weaker inhibitor of other aspartic proteases such as porcine pepsin or bovine cathepsin D (IC50 = 6 microM). It was shown not to be degraded by a rat liver homogenate preparation. In vivo, it inhibited plasma renin activity and lowered blood pressure of furosemide-treated cynomolgus monkeys. At a dose of 5 mg/kg iv, the pronounced hypotensive response persisted for greater than 3 h postinfusion.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3531518     DOI: 10.1021/jm00160a049

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  The selectivity of statine-based inhibitors against various human aspartic proteinases.

Authors:  R A Jupp; B M Dunn; J W Jacobs; G Vlasuk; K E Arcuri; D F Veber; D S Perlow; L S Payne; J Boger; S de Laszlo
Journal:  Biochem J       Date:  1990-02-01       Impact factor: 3.857

2.  Development of a sensitive activity assay for high-volume evaluation of human renin inhibitory peptides in rat serum: results with U-71,038.

Authors:  M J Ruwart; S K Sharma; D W Harris; D B Lakings; B D Rush; K F Wilkinson; J C Cornette; D B Evans; J M Friis; K J Cook
Journal:  Pharm Res       Date:  1990-04       Impact factor: 4.200

Review 3.  Renin inhibitors.

Authors:  W J Greenlee
Journal:  Pharm Res       Date:  1987-10       Impact factor: 4.200

4.  Prodrugs of peptides. 9. Bioreversible N-alpha-hydroxyalkylation of the peptide bond to effect protection against carboxypeptidase or other proteolytic enzymes.

Authors:  H Bundgaard; G J Rasmussen
Journal:  Pharm Res       Date:  1991-03       Impact factor: 4.200

5.  Development of a Therapeutic Peptide for Cachexia Suggests a Platform Approach for Drug-like Peptides.

Authors:  Kenneth A Gruber; Ren-Lai Ji; Fabio Gallazzi; Shaokai Jiang; Steven R Van Doren; Ya-Xiong Tao; Jessica Newton Northup
Journal:  ACS Pharmacol Transl Sci       Date:  2022-04-14

6.  Development of activity assays for high-volume evaluation of human immunodeficiency virus (HIV) protease inhibitors in rat serum: results with ditekiren.

Authors:  K F Wilkinson; B D Rush; S K Sharma; D B Evans; M J Ruwart; J M Friis; M J Bohanon; P K Tomich
Journal:  Pharm Res       Date:  1993-04       Impact factor: 4.200

7.  In vitro evaluation of the plasma and blood compatibility of a parenteral formulation for ditekiren, a novel renin inhibitor pseudopeptide.

Authors:  J C Greenfield; S J Loux; V K Sood; K M Jenkins; S R Davio
Journal:  Pharm Res       Date:  1991-04       Impact factor: 4.200

8.  Development, evaluation and application of 3D QSAR Pharmacophore model in the discovery of potential human renin inhibitors.

Authors:  Shalini John; Sundarapandian Thangapandian; Mahreen Arooj; Jong Chan Hong; Kwang Dong Kim; Keun Woo Lee
Journal:  BMC Bioinformatics       Date:  2011-12-14       Impact factor: 3.169

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.